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Reporting of Systematic Reviews: 
The Challenge of Genetic Association 
Studies
Muin J. Khoury, Julian Little, Julian Higgins, John P. A. 
Ioannidis, Marta Gwinn
We applaud PLoS editors for their commitment to publishing 
high-quality systematic reviews (SRs) [1]. Moher et al. [2] 
clearly documented the inconsistent quality of reporting 
of SRs. With more than 2,500 SRs published every year, 
low-quality or outdated reviews may mislead researchers, 
providers, and policy makers. The situation could be 
improved if more evidence-based reporting guidelines were 
agreed upon, developed, and adhered to.
The growing ﬁ  eld of genetic associations (GAs) illustrates 
the urgent need for transparent SRs and meta-analyses. 
Already, thousands of articles on GAs have been published, 
and the application of high-throughput genotyping methods 
may exponentially increase the number of reported 
associations [3]. Selective reporting of large numbers of false-
positive associations could undermine the ﬁ  eld and interfere 
with our ability to translate advances in genomics into clinical 
practice.
To address these problems, the Human Genome 
Epidemiology Network (HuGENet) was started as a global 
collaboration to strengthen methods of analysis and reporting 
of GAs and to develop a reliable knowledge base on the 
association between genetic variation and human diseases  
[4]. Between 2001 and 2006, the HuGENet online database 
assembled more than 25,000 published articles on GAs and 
more than 500 systematic reviews of GAs. Nevertheless, there 
are large inconsistencies in the quality of genetic association 
studies [5] and in the reporting of SRs of such associations 
[6]. In collaboration with several journals, HuGENet 
promotes the publication of transparently reported SRs of 
gene–disease associations [4]. More than 50 HuGE reviews 
have been published over the past six years. 
After several HuGENet workshops bringing together 
researchers from different ﬁ  elds and journal editors, the ﬁ  rst 
edition of a HuGENet handbook, modeled in part after the 
Cochrane handbook of systematic reviews, was published 
on the Canadian HuGENet Web site [7]. The handbook 
describes methodological issues and outlines steps in 
conducting such reviews, including the need for a detailed 
protocol. It also discusses meta-analysis methods. We strongly 
encourage researchers interested in conducting systematic 
reviews of GAs to consult the HuGENet handbook, and adopt 
transparent protocols. Retrospective SRs of published data 
have limitations, even when properly conducted. Investigators 
can advance the ﬁ  eld of human genome epidemiology by 
conducting prospective meta-analyses and large collaborative 
analyses through international consortia. HuGENet has 
created a Network of Investigator Networks to help the 
growth of such initiatives [8].  
Muin J. Khoury (muk1@cdc.gov)
Marta Gwinn
Centers for Disease Control and Prevention





Institute of Public Health
Cambridge, United Kingdom
John P. A. Ioannidis
University of Ioannina School of Medicine
Ioannina, Greece
References
1. The  PLoS Medicine Editors (2007) Many reviews are systematic but some are 
more transparent and completely reported than others. PLoS Med 4: e147. 
doi:10.1371/journal.pmed.0040147
2.  Moher D, Tetzlaff J, Tricco AC, Sampson M, Altman DG (2007) 
Epidemiology and reporting characteristics of systematic reviews. PLoS Med 
4: e78. doi: 10.1371/journal.pmed.0040078
3.  Khoury MJ, Little J, Gwinn M, Ioannidis JP (2006) On the synthesis and 
interpretation of consistent but weak gene-disease associations in the era of 
genome-wide association studies. Int J Epidemiol. E-pub 20 December 2006.
4.  Centers for Disease Control and Prevention (2007) Human Genome 
Epidemiology Network (HuGENet). Available: http://www.cdc.gov/
genomics/hugenet/default.htm. Accessed 24 May 2007.
5.  Bogardus ST Jr, Concato J, Feinstein AR (1999) Clinical epidemiological 
quality in molecular genetic research: The need for methodological 
standards. JAMA 281: 1919–1926.
6.  Attia J, Thakkinstian A, D’Este C (2003) Meta analysis of molecular 
association studies: Methodologic lessons for genetic epidemiology. J Clin 
Epidemiol 56: 297–303. 
7.  Little J, Higgins J, editors (2006) The HuGENet HuGE review handbook, 
version 1.0. Available: http://www.genesens.net/_intranet/doc_nouvelles/
HuGE%20Review%20Handbook%20v11.pdf. Accessed 24 May 2007.
8.  Ioannidis JP, Gwinn M, Little J, Higgins JP, Bernstein JL, et al. (2006) A 
road map for efﬁ  cient and reliable human genome epidemiology. Nat 
Genet 38: 3–5.
Citation: Khoury MJ, Little J, Higgins J, Ioannidis JPA, Gwinn M (2007) Reporting of 
Systematic Reviews: The challenge of genetic association studies. PLoS Med 4(6): 
e211. doi:10.1371/journal.pmed.0040211
Copyright: This is an open-access article distributed under the terms of the 
Creative Commons Public Domain Declaration, which stipulates that, once placed 
in the public domain, this work may be freely reproduced, distributed, transmitted, 
modiﬁ  ed, built upon, or otherwise used by anyone for any lawful purpose.
Funding: The authors received no speciﬁ  c funding for this article. 
Competing Interests: The authors have declared that no competing interests exist.
Reporting of Systematic Reviews: 
Better Software Required
Jan Brogger
This is an important paper and editorial [1,2]. Systematic 
reviews should be much more widespread, and not only for 
randomized clinical trials of clinical treatments. A paper on 
an elegant piece of experimental data or on epidemiological 
observations would be made all the more interesting if the 
ﬁ  rst table were a high-quality assessment of previous studies. 
In fact, I would suggest that performing a systematic review 
should be part of a research protocol for any subject, even 
before the study is initiated. However, this paper conﬁ  rms my 
suspicion that the rising popularity of “systematic reviews” has 
not been followed by adherence to methodological rigor.
With this background, I would like to point out one 
weakness that may explain part of the current quality deﬁ  cit in 
some systematic reviews. There is a substantial lack of software 
that can assist in an important part of a systematic review: 
tracking literature searches and early phase screening. From PLoS Medicine  |  www.plosmedicine.org 1130
browsing of the literature and communications with various 
Norwegian and Danish Cochrane collaborators (including the 
RevMan developers), there seems to be a limited number of 
tools for this use. Oftentimes, it is suggested that commercial 
reference management software be used, such as the popular 
EndNote. These types of software were not designed with 
systematic reviews in mind. At later stages of a review, 
Cochrane’s RevMan is useful, but not early on.
As far as I have been able to ascertain, there are only 
two tools presently available. The ﬁ  rst is EPPI-Reviewer 
(http:⁄⁄eppi.ioe.ac.uk/cms/Default.aspx?tabid=184), which is 
non-proﬁ  t, but does not seem to be open source or available 
for local deployment. The second is TrialStat’s SRS software 
(http://www.trialstat.com), which is commercial and has a 
substantial price tag.
I would therefore encourage researchers and institutions 
to contribute to the development of open-source tools for 
assisting in systematic reviews. I am currently writing such 
a simple tool, based on the open-source JabRef package 
(http://sourceforge.net/projects/jabref) and would welcome 
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Neuraminidase Antibodies and H5N1: 
Geographic-Dependent Inﬂ  uenza 
Epidemiology Could Determine Cross-
Protection against Emerging Strains
Jesus F. Bermejo-Martin, David J. Kelvin, Yi Guan, 
Honglin Chen, Pilar Perez-Breña, Inmaculada Casas, 
Eduardo Arranz, Raul O. de Lejarazu
We have read with great interest the work of Sandbulte et 
al. recently published in your journal [1]. In this article, the 
authors provide evidence for the existence of cross-immunity 
between the neuraminidase of H5N1 viruses and that of 
endemic human H1N1 viruses. Age may be an important 
determining factor in the development of cross-immunity: 
younger people, having a shorter history of H1N1 exposure, 
may be disproportionately susceptible to H5N1 infection.
We would like to highlight the inﬂ  uence of the geographic-
dependent epidemiological behaviour of inﬂ  uenza in the 
development of cross-immunity. While Europe, the United 
States, and northern Asia experience regular outbreaks 
of inﬂ  uenza each year, (“seasonal inﬂ  uenza”), inﬂ  uenza 
in tropical regions such as southern China, Vietnam, and 
Indonesia tends to be year-round (“non-seasonal” inﬂ  uenza). 
In consequence, the probability of exposure to inﬂ  uenza A in 
these regions persists throughout the entire year. Repetitive 
contacts with inﬂ  uenza wild viruses could promote the 
development of cross-immunity against different viral strains. 
Even more, it could represent a fortuitous mechanism for 
developed natural protection by the close and persistent 
exposure of the immune system to inﬂ  uenza wild viruses in 
regions known for being an important source of emergent 
viruses, like southern China.
Results from Sandbulte et al. show that antibodies play a 
dominant role in cross-protection. The authors underscore 
the possible beneﬁ  t of seasonal inﬂ  uenza vaccination for 
human populations faced with the threat of pandemic H5N1 
inﬂ  uenza. This idea deserves careful analysis. The main 
group at risk for severe complications of seasonal ﬂ  u are 
people older than 65. In Western countries, this population 
is recommended to receive annual vaccinations. Generally 
speaking, elder vaccination rates in tropical countries are 
far lower than those in Western countries. Even with the low 
annual vaccination rate in elders, H5N1 infection is observed 
mostly in young people. The existence of sub-clinical or 
asymptomatic infections in elderly people cannot be ruled 
out, but the reason why there are no described clinical 
cases of H5N1 in people older than 40 years is currently 
unknown. An age-dependent differential distribution of 
avian-type receptors in the upper respiratory tract could 
be a possible explanation. On the other hand, Tumpey et 
al. [2] demonstrated that mucosal (but not parenteral) 
challenges with inactivated or live H3N2 virus protect against 
H5N1 infection in mice. These results could have a relevant 
consequence: does contact with circulating inﬂ  uenza A 
via the respiratory tract confer a higher degree of cross-
protection than parenteral exposure to vaccines? 
In conclusion, the non-seasonal epidemiological behaviour 
of inﬂ  uenza in tropical countries could dramatically inﬂ  uence 
the development of naturally induced cross-immunity against 
different inﬂ  uenza strains and diminish the risk of severe 
disease from new emergent strains in elderly people living 
in these countries. The apparent lack of H5N1 cases in the 
elderly may be the result of continued exposure to circulating 
non-seasonal inﬂ  uenza A via mucosal epithelium in the 
respiratory tract. Vaccination via the mucosal route could be 
a more efﬁ  cient way to provide cross-protection against future 
pandemic strains than vaccination via the parenteral route. In 
this hypothetical scenario, Western countries would be under-
protected.  
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Lethal Injection: Let’s Be Honest about 
the Death Penalty
Lawrence Bonchek
I don’t favor the death penalty, and I don’t participate 
in executions, but I recognize that honorable people can 
disagree about the subject, and I don’t consider physicians 
who wish to do so—to assure that death comes quickly and 
without unusual pain—to be behaving unethically. They 
could be seen as serving the interests of both the condemned 
and society.
The conundrum about lethal injection persists only 
because long-standing American Medical Association 
guidelines prohibit physicians from carrying out actual 
executions, or even pronouncing death, though they may 
certify it—a distinction without a difference. The lack of 
physician involvement has resulted in execution protocols 
based on outmoded pharmacologic methods, carried out 
by inconsistently qualiﬁ  ed technicians, with results that are 
sometimes ineffective and therefore are understandably 
controversial.
Any qualiﬁ  ed anesthesiologist could propose more reliable 
techniques. It is unreasonable to assert that a condemned 
person cannot be executed painlessly, when tens of thousands 
of people are anesthetized every single day for surgery with 
modern fast-acting anesthetic drugs (propofol, in particular) 
that are far more suitable than the outmoded execution drug 
thiopental. Induction of surgical anesthesia does occasionally 
cause slight injection pain, so how then can it be “cruel and 
unusual” to use the same drug and method for the initial step 
in executions? Next, potassium cannot fail to stop the heart 
instantly and insensibly if given in substantial amounts.
The debate about the death penalty should be conducted 
about its morality, not about its methods, because the latter 
is merely a surrogate for serious debate. Opponents of the 
death penalty (like me) should recognize that it is unwise to 
criticize methods alone, because improved methods vitiate 
those arguments [1].  
Lawrence Bonchek (lbonchek@yahoo.com)
Lancaster General Hospital
Lancaster, Pennsylvania, United States of America
References
1. The  PLoS Medicine Editors (2007) Lethal injection is not humane. PLoS 
Med 4: e171. doi:10.1371/journal.pmed.0040171
Citation: Bonchek L (2007) Lethal Injection: Let’s be honest about the death 
penalty. PLoS Med 4(6): e213. doi:10.1371/journal.pmed.0040213
Copyright: © 2007 Lawrence Bonchek. This is an open-access article distributed 
under the terms of the Creative Commons Attribution License, which permits 
unrestricted use, distribution, and reproduction in any medium, provided the 
original author and source are credited.
Funding: The author received no speciﬁ  c funding for this article. 
Competing Interests: The author has declared that no competing interests exist.
Lethal Injection: Other Views
The PLoS Medicine Editors
The recently published research article on lethal injection [1] 
and our editorial commentary [2] both produced a number 
of short letters via our electronic reader response system.
There were ﬁ  ve letters commenting on the research 
article. All were written by strong supporters of the death 
penalty who took the view that, as the victims of those who 
had been convicted of murder had suffered, the perpetrators 
should themselves experience pain as well as execution. We 
posted two of these letters on our Web site, but felt the other 
three were written in terms that made them unsuitable for 
inclusion.
Our editorial attracted 11 letters. Three supported 
the views we had expressed, one commented on a small 
factual error, and seven were hostile, again focusing on the 
desirability of making murderers suffer. We felt that one of 
the supportive letters (above) was of particular interest and 
we have therefore chosen to highlight it by means of formal 
publication in the Correspondence section of the journal. Of 
the seven hostile letters, we considered that four were suitable 
for posting on the Web site.
We do not intend, within our Correspondence section, 
to publish further letters commenting on the research 
article or the editorial. However, as with all the articles we 
publish, reader responses for the Web site may be submitted 
at any time. After a very brief screening for suitability, 
reader responses appear on the site within a day or two of 
submission.  
The PLoS Medicine Editors
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Consent for Genomic Epidemiology in 
Developing Countries: Added Human 
Subject Protection Also Needed
Robert Reinhard
The authors deserve thanks for laying out decent principles 
of communication [1]. But serviceable consent language is 
insufﬁ  cient to address all issues of protection. That was the 
point of recent workshops held by the National Institutes of 
Health to develop a genome-wide association studies program 
[2].
Risks associated with personal identiﬁ  cation may be 
incurred if information is subject to code breaking. Legal 
means are available to compel identiﬁ  cation, including 
across national boundaries. Privacy protections under the 
Health Insurance Portability and Accountability Act (HIPAA) 
are subject to exceptions, including for law enforcement, 
downstream data users, or for other reasons, and are not 
available internationally. Even with authorization, the 
complexities associated with a repository may frustrate 
attempts to achieve meaningful comprehension. Use of 
data for purposes other than pharmaceutical product 
development or biomedical interventions would be an abuse 
resulting perhaps in travel restrictions or discrimination.
For these reasons, safeguards should be added, including:
•  Amendments to prevent non-medical health access to 
personal identiﬁ  cation information;
•  Restrictions on recruitment of populations especially 
vulnerable to disclosure risks, such as prisoners or 
immigrants;
•  Prohibitions on disclosure to or use by employers or 
third-party payors to deny medical coverage, assign 
differential premium risks, restrict access to therapies, or 
unfairly discriminate in employment.
Another risk from creation of a genomics repository is 
the potential for unjust stigmatization (see for example 
[3]). A workable program would state that the data are 
appropriate only for limited public health purposes involving 
product development or professionally derived biomedical 
intervention, and are insupportable for other use or by 
political or non-medical entities.
A researcher publishing results based on the genomic data 
should state afﬁ  rmatively a boilerplate recognition of the 
abuse potential for stigmatization. This mechanism could 
prevent others from the wayward misappropriation of data 
for purposes other than those intended by professionals. The 
boilerplate could read:
“Conclusions derived from the genotypic or phenotypic 
characterization of individuals, groups, or families in this 
[publication] are meaningful or supportable only for the 
purpose of biomedical intervention or treatment and 
are unethical, insupportable, or inappropriate for use in 
other purposes. Use of the data to support any result of 
stigmatization, discrimination, or adverse social harm would 
constitute a misuse or abuse of the data.”
To increase the connection of beneﬁ  ts to participants, 
individuals should be given personal opportunities to receive 
news reports if they wish and learn of particular clinical trials 
directed at their characteristics. If the data are to be used in 
the development of pharmaceutical products, users should 
also be directed to plan and explain early on how targeted 
populations may have reasonable access to treatment or 
therapy if the product is successfully brought to market. 
These suggestions are consistent with the program outlined 
by Senator Barack Obama in the Genomics and Personalized 
Medicine Act of 2006 and Senator Olympia Snowe in the 
Genetic Information Nondiscrimination Act of 2007 [4,5].
Improved consent: Yes, but linked to and inseparable from 
strong protections and added beneﬁ  ts for participants.  
Robert Reinhard (rreinhard@mofo.com)
San Francisco Vaccine Trials Unit
San Francisco, California, United States of America
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Why Most Published Research Findings 
Are False: Author’s Reply to Goodman 
and Greenland
John P. A. Ioannidis
I thank Goodman and Greenland for their interesting 
comments [1] on my article [2]. Our methods and results 
are practically identical. However, some of my arguments are 
misrepresented:
1. I did not “claim that no study or combination of studies 
can ever provide convincing evidence.” In the illustrative 
examples (Table 4), there is a wide credibility gradient (0.1% 
to 85%) for different research designs and settings.
2. I did not assume that all signiﬁ  cant p-values are around 
0.05. Tables 1–3 and the respective positive predictive value 
(PPV) equations can use any p-value (alpha). Nevertheless, 
the p = 0.05 threshold is unfortunately entrenched in many 
scientiﬁ  c ﬁ  elds. Almost half of the “positive” ﬁ  ndings in 
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recent observational studies have p-values of 0.01–0.05 [3,4]; 
most “positive” trials and meta-analyses also have modest p-
values.
3. I provided equations for calculating the credibility of 
research ﬁ  ndings with or without bias. Even without any bias, 
PPV probably remains below 0.50 for most non-randomized, 
non-large-scale circumstances. Large trials and meta-analyses 
represent a minority of the literature.
4. Figure 1 shows that bias can indeed make a difference. 
The proposed modeling has an additional useful feature: As 
type I and II errors decrease, PPV(max) = 1 − [u/(R + u)], 
meaning that to allow a research ﬁ  nding to become more 
than 50% credible, we must ﬁ  rst reduce bias at least below 
the pre-study odds of truth (u less than R). Numerous studies 
demonstrate the strong presence of bias across research 
designs: indicative reference lists appear in [5–7]. We should 
understand bias and minimize it, not ignore it.
5. “Hot ﬁ  elds”: Table 3 and Figure 2 present “the 
probability that at least one study, among several done on 
the same question, claims a statistically signiﬁ  cant research 
ﬁ  nding.” They are not erroneous. Fields with many furtive 
competing teams may espouse signiﬁ  cance-chasing behaviors, 
selectively highlighting “positive” results. Conversely, having 
many teams with transparent availability of all results and 
integration of data across teams leads to genuine progress. 
We need replication, not just discovery [5].
6. The claim by two leading Bayesian methodologists that 
a Bayesian approach is somewhat circular and questionable 
contradicts Greenland’s own writings: “One misconception 
(of many) about Bayesian analyses is that prior distributions 
introduce assumptions that are more questionable than 
assumptions made by frequentist methods” [8].
7. Empirical data on the refutation rates for various 
research designs agree with the estimates obtained in the 
proposed modeling [9], not with estimates ignoring bias. 
Additional empirical research on these fronts would be very 
useful.
Scientiﬁ  c investigation is the noblest pursuit. I think we can 
improve the respect of the public for researchers by showing 
how difﬁ  cult success is. Conﬁ  dence in the research enterprise 
is probably undermined primarily when we claim that 
discoveries are more certain than they really are, and then the 
public, scientists, and patients suffer the painful refutations.  
John P. A. Ioannidis (jioannid@cc.uoi.gr)
University of Ioannina School of Medicine 
Ioannina, Epirus, Greece
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Biomedical Journals and Global 
Poverty: Is HINARI a Step Backwards?
Javier Villafuerte-Gálvez, Walter H. Curioso, 
Oscar Gayoso
Much has been written about how open access to biomedical 
journals is vital for researchers in developing countries [1], 
but so much more needs to be done.
Our experience in Peru with the Health InterNetwork 
Access to Research Initiative (HINARI), an initiative managed 
by the World Health Organization that helps promote access 
to scientiﬁ  c information by providing free (or low cost) 
online access to major science journals, is not as accessible 
as hoped for and, in fact, is getting worse. When HINARI 
launched in 2003, it provided access to more than 2,300 
major journals in biomedical and related social sciences [2]. 
In April 2007, we conducted a review of the ﬁ  rst 150 
science journals available through HINARI with the 
highest impact factors on the Science Citation Index [3]. 
We excluded open-access journals and journals that make 
online access free to low-income countries (e.g., The New 
England Journal of Medicine, British Medical Journal Publishing 
Group). We could not access any of the top ﬁ  ve journals from 
major publishers such as Nature and Elsevier-Science Direct. 
In other words, from the Nature Publishing Group we had 
no access to Nature Reviews Cancer, Nature Reviews Immunology, 
Nature Reviews Molecular Cell Biology, Nature, or Nature 
Medicine, and from Elsevier ScienceDirect we had no access 
to Cell, Cancer Cell, Current Opinion in Cell Biology, Immunity, 
or Molecular Cell. In addition, we could not access any of the 
ﬁ  rst-level journals from Blackwell, Oxford Press University, 
Lippincott Williams and Wilkins, or Wiley and Sons. In 2003, 
all these journals were available.
Our ﬁ  ndings support comments received from users over 
the last 8–10 months at the main library at Universidad 
Peruana Cayetano Heredia (Oscar Gayoso, personal 
communication). Students and faculty could not get access 
to biomedical journals from Nature, Elsevier-Science Direct, 
Blackwell, Oxford Press University, Springer Science, 
Lippincott Williams and Wilkins, or Wiley and Sons through 
HINARI. The collections of journals from the above-
mentioned publishers together represent approximately 
57% (2,118 of 3,741) of journals that were supposed to 
be accessible through HINARI, while the remaining 43% 
accessible were largely composed of open-access journals or 
journals that make online access free to low-income countries.
Moreover, we have found a signiﬁ  cant decrease in the 
number of users accessing HINARI at our institution. For 
example, the number of HINARI users has decreased from 
June 2007  |  Volume 4  |  Issue 6  |  e215  |  e220PLoS Medicine  |  www.plosmedicine.org 1134
12,144 in April 2005 to 5,655 in April 2007, which may reﬂ  ect 
the loss of impact of the HINARI initiative at our institution. 
In contrast, the number of users accessing other databases 
such as ProQuest and EBSCO has increased over the last few 
months.
Our ﬁ  ndings suggest that we not only have access to a 
reduced number of biomedical journals on HINARI, but we 
also have no access to the biomedical journals that have the 
highest impact factors. The HINARI Web site states that it is 
still incorporating new journal collections. However, we are 
afraid that any addition that will not provide access to major 
publishers (such as the Nature Publishing Group, Elsevier 
ScienceDirect, or Lippincott Williams and Wilkins) could lack 
real impact according to HINARI’s goals.
Since 2003, Peruvian medical students and health 
professionals have substantially beneﬁ  ted from access to 
high-quality scientiﬁ  c information through HINARI. Few 
medical students and very few researchers in the developing 
world can pay the usual fee of US$20–US$45 to download 
one article. Not even some private universities in Peru 
can afford the minimum journal subscription rates, even 
though these subscriptions would help the universities to 
become less isolated from global medical research. Having 
to pay US$1,000 per year to HINARI has left many public 
universities in the provinces of Peru without access because 
they cannot afford it. Even for the Peruvian institutions that 
are currently paying US$1,000 per year to HINARI, what is 
the real beneﬁ  t of their HINARI subscription now? 
We fear that the loss of access to many key journals that are 
published by the major companies could be a major setback 
to the education of medical students in Peru and perhaps 
around the world. Furthermore, it could make biomedical 
research in developing countries like Peru, a key element in 
ﬁ  ghting poverty, even scarcer.
In conclusion, students and researchers in developing 
countries such as Peru, working at the frontlines of global 
health problems, need to access more biomedical journals 
in order to practice evidence-based health care and conduct 
high-quality research. The recent loss of access to many key 
biomedical journals in Peru could be a step backwards. We 
hope the situation described in this letter might help lend 
support to the proposal of Godlee et al., who suggested 
that the World Health Organization and its partners should 
take the lead in establishing an international collaborative 
group along the lines of the Global Fund to ﬁ  ght AIDS, 
Tuberculosis and Malaria to achieve the goal of “Universal 
access to essential health-care information by 2015” or 
“Health information for all” [4].  
Javier Villafuerte-Gálvez
Walter H. Curioso (wcurioso@u.washington.edu)
Oscar Gayoso
Universidad Peruana Cayetano Heredia
Lima, Peru
References
1. The  PLoS Medicine Editors (2006) How can biomedical journals help 
to tackle global poverty? PLoS Med 3: e380. doi:10.1371/journal.
pmed.0030380
2.  Aronson B (2002) WHO’s Health InterNetwork Access to Research 
Initiative (HINARI). Health Info Libr J 19: 164–165.
3.  Warschawski DR (2005) Journal impact factors. Available: http://www.ibpc.
fr/~dror/jif.html. Accessed 23 May 2007.
4.  Godlee F, Pakenham-Walsh N, Ncayiyana D, Cohen B, Packer A (2004) Can 
we achieve health information for all by 2015? Lancet 364: 295–300.
Citation: Villafuerte-Gálvez J, Curioso WH, Gayoso O (2007) Biomedical Journals 
and Global Poverty: Is HINARI a step backwards? PLoS Med 4(6): e220. doi:10.1371/
journal.pmed.0040220
Copyright: © 2007 Villafuerte-Gálvez et al. This is an open-access article distributed 
under the terms of the Creative Commons Attribution License, which permits 
unrestricted use, distribution, and reproduction in any medium, provided the 
original author and source are credited.
Funding: Preparation of this article was supported in part by a grant from 
the Fogarty International Center, United States National Institutes of Health 
(5D43TW007551).
Competing Interests: The authors have declared that no competing interests exist.
June 2007  |  Volume 4  |  Issue 6  |  e220